Evidence map›Paper›PMID 25809254›Full record

ArticleBiophysical journal2015

Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel.

Laura L Perissinotti, Jiqing Guo, Pablo M De Biase, Colleen E Clancy, Henry J Duff, Sergei Y Noskov

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Pharmacological activation of the hERG KJournal of arrhythmia · 2022
    Review
  3. Modeling the kinetics of heteromeric potassium channels.Frontiers in cellular neuroscience · 2022
    Article
  4. Calibration of ionic and cellular cardiac electrophysiology models.Wiley interdisciplinary reviews. Systems biology and medicine · 2020
    Review
  5. Four Ways to Fit an Ion Channel Model.Biophysical journal · 2019
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Laura L PerissinottiCentre for Molecular Modeling, Department of Biological Sciences, Faculty of Science, University of Calgary, Calgary, Alberta, Canada.
Jiqing GuoLibin Cardiovascular Institute of Alberta, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Pablo M De BiaseCentre for Molecular Modeling, Department of Biological Sciences, Faculty of Science, University of Calgary, Calgary, Alberta, Canada.
Colleen E ClancyDepartment of Pharmacology, University of California at Davis, Davis, California. Electronic address: ceclancy@ucdavis.edu.
Henry J DuffLibin Cardiovascular Institute of Alberta, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: hduff@ucalgary.ca.
Sergei Y NoskovCentre for Molecular Modeling, Department of Biological Sciences, Faculty of Science, University of Calgary, Calgary, Alberta, Canada. Electronic address: snoskov@ucalgary.ca.
University of Calgary · CALibin Cardiovascular Institute of Alberta · CAUniversity of California, Davis · US

Funding

Pharmacogenomics and antiarrhythmic therapy: An in silico investigationR01HL085592 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CLANCY, COLLEEN E · 2007 to 2011
$1.8M
Canadian Institutes of Health Research 201103MOP-CSA-244888NHLBI NIH HHS R01 HL085592NHLBI NIH HHS R01-HL-085592
6 · The paper itself

Abstract

Congenital and acquired (drug-induced) forms of the human long-QT syndrome are associated with alterations in Kv11.1 (hERG) channel-controlled repolarizing IKr currents of cardiac action potentials. A mandatory drug screen implemented by many countries led to a discovery of a large group of small molecules that can activate hERG currents and thus may act as potent antiarrhythmic agents. Despite significant progress in identification of channel activators, little is known about their mechanism of action. A combination of electrophysiological studies with molecular and kinetic modeling was used to examine the mechanism of a model activator (NS1643) action on the hERG channel and its L529I mutant. The L529I mutant has gating dynamics similar to that of wild-type while its response to application of NS1643 is markedly different. We propose a mechanism compatible with experiments in which the model activator binds to the closed (C3) and open states (O). We suggest that NS1643 is affecting early gating transitions, probably during movements of the voltage sensor that precede the opening of the activation gate.

Indexed as

Models, MolecularCell LineCresolsERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsHumansKineticsMembrane PotentialsMembrane Transport ModulatorsMutationPatch-Clamp TechniquesPhenylurea CompoundsTransfection1,3-bis(2-hydroxy-5-trifluoromethylphenyl)ureaCresolsERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsKCNH2 protein, humanMembrane Transport ModulatorsPhenylurea Compounds

Identifiers

PMID25809254
PMCPMC4375712
OpenAlexW2009050401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.